Page 77 - Looking Statements News Today

Q4 fiscal 2023 net sales increased 6.3%Q4 fiscal 2023 comparable store sales grew 2.7% driven by a 7.5% increase in transactionsCompany provides o...

TKO Transaction Highlights On September 12, 2023, Endeavor and WWE closed the transaction to combine UFC and WWE to form a new, publicly listed company, TKO Group Holdings, Inc. The reported...

Civitas Resources, Inc. , today announced the execution of a definitive agreement to repurchase approximately 876 thousand shares of its common stock at a price of $64.54 per share from NGP Tap Rock...

Consolidated Results of Operations - Three-Month Periods Ended December 31, 2023 and 2022: KING OF PRUSSIA, Pa., Feb. 27, 2024 /PRNewswire/ -- Universal Health Realty Income Trust announced today...

DENVER, February 27, 2024--Civitas Resources, Inc. (NYSE: CIVI) ("Civitas" or the "Company"), today announced the execution of a definitive agreement to repurchase approximately 876 thousand shares of its common stock at a price of $64.54 per share from NGP Tap Rock Holdings, LLC and certain of its affiliates ("NGP"). The transaction was approved by the Company’s Board of Directors, and the repurchase is expected to close in early March 2024. Following the tr...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S.  SIMLANDI is the first biosimilar...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...

Brazilian Delegation of Senior Authorities Visits Aclara’s Heavy Rare ...